Search research articles

Search research articles

Related Experiment Videos

Therapeutic developments in sudden cardiac death.

J J Goldberger¹, S Neelagaru

¹Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois, USA. j-goldberger@northwestern.edu

Expert Opinion on Investigational Drugs

|November 4, 2000

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Utility of exercise testing to assess athletes for post COVID-19 myocarditis.

American heart journal plus : cardiology research and practice·2022

Same author

Diagnosis of cellulitis in patients infected with the human immunodeficiency virus.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012

Same author

Prevention of sudden cardiac death.

Heart disease (Hagerstown, Md.)·2001

Same author

Effectiveness of shielding for patients during cardiac catheterization or electrophysiologic testing.

The American journal of cardiology·2001

Same author

Over-AVID subgroup analysis.

Journal of the American College of Cardiology·2001

Same author

Atrioventricular junction ablation performed via a patent foramen ovale.

Journal of cardiovascular electrophysiology·2001

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Sudden cardiac death, often caused by ventricular tachyarrhythmias, requires effective prevention strategies. While beta-blockers and amiodarone show some utility, implantable cardioverter-defibrillators are most effective for high-risk individuals.

Area of Science:

Cardiology
Electrophysiology
Pharmacology

Background:

Sudden cardiac death (SCD) is characterized by unexpected mortality in clinically stable individuals.
Ventricular tachyarrhythmias are a frequent cause of SCD, with poor survival rates for out-of-hospital cardiac arrest.
Developing effective prevention strategies is crucial for improving patient outcomes.

Purpose of the Study:

To review current and emerging treatment strategies for preventing sudden cardiac death.
To evaluate the efficacy of pharmacological agents and device-based therapies.
To highlight the need for improved risk stratification in patients susceptible to SCD.

Main Methods:

Review of existing literature on pharmacological interventions (beta-blockers, anti-arrhythmics) and device therapies.

Related Experiment Videos

Analysis of clinical trial data and expert consensus regarding sudden cardiac death prevention.

Exploration of novel approaches, including genetic analysis for risk stratification.

Main Results:

Beta-blockers are beneficial post-myocardial infarction and in heart failure, with potential roles in other cardiac conditions.
Most anti-arrhythmic agents are not effective for prophylactic prevention of SCD mortality, with amiodarone being a potential exception in specific subgroups.
The implantable cardioverter-defibrillator (ICD) is the most effective therapy for preventing SCD in high-risk patient populations.

Conclusions:

Enhanced characterization of high-risk patients is necessary for targeted SCD prevention.
Genetic analyses in cardiovascular disorders may reveal new avenues for preventing sudden cardiac death.
A multi-faceted approach combining risk stratification, pharmacological management, and device therapy is essential for SCD prevention.